Seeking Alpha

Novo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed...

Novo Nordisk (NVO -0.9%) slips after an FDA review of its basal insulin degludec gets postponed yet again. The review was pushed back to November after being delayed once before in June, as the agency continues to seek outside experts for a review. Degludec is a long-lasting insulin drug designed to compete with Sanofi's (SNY +2.5%) similar product Lantus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs